

We would also like to take this opportunity to inform you of the **latest information received from GSK about their product VIR-7831**.

“Outcome of today’s Independent Data Monitoring Committee (IDMC) meeting for the Phase 3 COMET-ICE trial for VIR-7831: After reviewing the data, the IDMC recommended that the trial be stopped for enrollment due to evidence of overwhelming efficacy.

*The IDMC recommendation was based on an interim analysis of data from 583 patients enrolled in the COMET-ICE trial, which demonstrated an **85% (p-value=0.002) reduction in hospitalization or death in patients receiving VIR-7831 as monotherapy** compared to placebo, the primary endpoint of the trial.*

In addition GSK also announced today the results of a new study submitted and pending online publication in bioRxiv, demonstrating that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants, based on in vitro data from pseudotyped virus assays. In contrast to other monoclonal antibodies, VIR-7831 binds to a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop.

Please find attached a press release just published providing some additional information.”

Kind regards,

The Joint Procurement Agreement Team

* Not for distribution. Do not read or carry openly in public places. Must be stored securely and encrypted in storage and transmission. Destroy copies by shredding or secure deletion. Full handling instructions: <https://europa.eu/db43PX>